# Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer

> **NCT07059949** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 80 (estimated)

## Conditions studied

- Unresectable Metastatic Rectal Cancer
- CAPOX
- Combination of Radioimmunotherapy

## Interventions

- **DRUG:** CAPOX+ Camrelizumab+ Cetuximab
- **DRUG:** CAPOX+ Camrelizumab+ Bevacizumab

## Key facts

- **NCT ID:** NCT07059949
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2027-01-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07059949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07059949, "Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07059949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*